Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

186.26 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
99 100 Next >
Generating Passive Income: 3 Top Dow Dividend Stocks to Buy for 2025 and Beyond
Via The Motley Fool
Topics Bonds Stocks
Elon Musk Commits to Tesla. Is That a Good Thing?
Via The Motley Fool
Value Investing Is Not Dead - It Just Got Smarter
 
Via Benzinga
FDA Panel Reiterates the Cancer Risks of Talc
From Beasley Allen Law Firm
Via Business Wire
This Healthy High-Yielding Dividend Stock Just Increased Its Payment for the 48th Year in a Row
Via The Motley Fool
Topics World Trade
3 Buy-and-Hold Stocks Long-Term Investors Can Love in Any Market
For buy-and-hold investors looking for some quality names to navigate a turbulent market, here are three stocks to consider 
Via MarketBeat
Topics ETFs Economy
Johnson & Johnson to Participate in the Bernstein’s 41st Annual Strategic Decisions Conference
From Johnson & Johnson
Via Business Wire
Apple, Nvidia, GM: CEOs Are Talking About Being American-Made Again
US companies are reshoring manufacturing operations & investing billions in the country, led by Apple & Nvidia for tech, J&J & Eli Lilly for healthcare, Anheuser-Busch for beer, & Cra-Z-Art for toys.... 
Via Benzinga
Market Whales and Their Recent Bets on JNJ Options
 
Via Benzinga
Meet the Warren Buffett Investment That's Gained 5,502,284% and Looks Set to Soar Even Higher
Warren Buffett has had a lot of successful investments, but one in particular has crushed the stock market time and again. 
Via The Motley Fool
3 Magnificent Stocks That Are Passive Income Machines
Via The Motley Fool
US-China Trade Truce, Trump's Middle East Deals Spark Wall Street Rally: This Week In Markets
U.S. and China cut tariffs by 115 points, sparking a stock rally and improving trade outlook. Trump secures $2 trillion in Gulf deals. 
Via Benzinga
Topics Government World Trade
Nachawati Law Group Files New Ovarian Cancer Lawsuits Against Johnson & Johnson After Latest Bankruptcy Ploy Fails
From Nachawati Law Group
Via Business Wire
Why Pfizer Is Poised For A Strong Comeback: My Top Pick For 2025
For investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare buying opportunity. 
Via Benzinga
Jim Cramer Says Even 'Safety' Stocks Look Risky, Warns Of 'Wild Card' In Washington And Rising Treasury Yields As Reasons To Stay Away From Sure Bets
Rising bond yields and uncertain politics make 'safety' stocks less appealing, says Jim Cramer. Even Procter & Gamble and Johnson & Johnson suddenly feel shaky to the market guru. 
Via Benzinga
Topics Bonds
Johnson & Johnson to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
From Johnson & Johnson
Via Business Wire
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030
Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states. 
Via Benzinga
CMS Expands Medicare Drug Price Talks To Part B Meds In 2026 Shake Up
CMS draft expands drug price talks to include Medicare Part B drugs and outlines steps for future renegotiations; public comments due by June 26. 
Via Benzinga
The Smartest Dividend Stocks to Buy With $5,000 Right Now
Via The Motley Fool
Topics Economy Retirement
Trump Unveils 'Historic And Transformative' $600 Billion Saudi Deal, Predicts Markets Will 'Go A Lot Higher'
President Trump unveils a $600 billion Saudi investment package into the U.S., with major deals in tech, defense, energy, and healthcare. 
Via Benzinga
Topics Government
13 Analysts Have This To Say About Johnson & Johnson
 
Via Benzinga
Peering Into Johnson & Johnson's Recent Short Interest
 
Via Benzinga
Top Biotech Halozyme Undercuts Its Breakout On Bad Medicare News
It's biggest product will be up for price negotiations under the Inflation Reduction Act much sooner than expected. 
Via Investor's Business Daily
Topics Economy Government
Top S&P500 movers in Monday's pre-market session
Stay updated with the S&P500 stocks that are on the move in today's pre-market session. 
Via Chartmill
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform
It's still unclear how President Donald Trump plans to tie drug prices in the U.S. to international prices. 
Via Investor's Business Daily
Topics Government Stocks
Mark Cuban Slams Charlie Kirk Over Drug Price Debate, Says PBMs — Not Big Pharma — Are The Real Villains: 'For Your Company...Ask Your PBM For A List Of Claims'
Mark Cuban, the billionaire entrepreneur, challenged Trump-supporter and political activist Charlie Kirk's stance on high drug prices, asserting that Pharmacy Benefit Managers (PBMs) are the main... 
Via Benzinga
Cathie Wood Says AI Innovation In Healthcare Will Be More 'Profound' Than Autonomous Taxi Networks, Humanoid Robots
Cathie Wood highlights the rising applications of AI and how it is poised to impact the health care space. 
Via Benzinga
Topics Artificial Intelligence
Trump's New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&J Fall In Premarket
What Happened: On Sunday, President Donald Trump announced on Truth Social that he plans to sign what he called the "most consequential executive order" in U.S. history, aimed at lowering prescription... 
Via Benzinga
Topics Government
Trump Says Prescription Drug Prices Set To Drop By 30% To 80% 'Almost Immediately' Thanks To 'Most Favored Nation' Plan, Mark Cuban Urges President To 'Force Transparency'
Trump vows to slash drug prices with new executive order, potentially dropping them by 30-80%. 
Via Benzinga
Topics Government
Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study
Protagonist and J&J report strong Phase 3 psoriasis data for icotrokinra and unveil potent next-gen IL-17 blocker PN-881 at SID meeting. 
Via Benzinga
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.